Comparison of topoisomerase I and II expression in primary brain tumor and lung cancer

Oncology Reports

Volumn 4, Issue 4, 1997, Pages 857-861

  Savaraj, Niramol ^a   Xu, Rong ^a   Landy, Howard ^b   Lai, Shenghan ^b   Sternau, Linda ^b   Solomon, Jeannine ^a   Wu, Chun Jing ^a   Lampidis, Theodore ^b   Feun, Lynn G ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Brain tumor; Lung cancer; Topoisomerase I and II

Indexed keywords

ANTHRACYCLINE; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); MITOXANTRONE;

ADULT; ARTICLE; BRAIN CANCER; CANCER GRADING; CATALYSIS; CLINICAL ARTICLE; CRANIOTOMY; DNA DETERMINATION; DNA STRAND BREAKAGE; ENZYME ACTIVITY; EUKARYOTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LUNG CANCER; PRIORITY JOURNAL; REGRESSION ANALYSIS;

EID: 0030876957     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.4.4.857     Document Type: Article

References (28)

1. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
2. Bleiberg H and Rothenberg M: CPT-11: from DNA topology to clinical activity. Semin Oncol 23 (Suppl 3): No 1, 42-50, 1996.
3. Schiller JH, Kim KM, Hutson P, Devore R, Glich J, Stewart J and Johnson D: Phase II study of topotecan in patients with extensive stage small cell lung carcinoma of the lung: an Eastern Cooperative Group trial. J Clin Oncol 14: 2345-2352, 1996.
4. Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T and Saijo N: Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84: 113-118, 1992.
5. Gazdar AF, Steinberg SM and Russell EK: Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage SCLC: a prospective clinical trial. J Natl Cancer Inst 82: 117-124, 1990.
6. Wolverton JS, Danks MK, Granzen B and Beck WT: DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors. Cancer Res 52: 4248-4253, 1992.
7. Doyle LA: Topoisomerase expression in cancer cell lines and clinical samples. Cancer Chemother Pharmacol 34 (Suppl): 32-40, 1994.
8. Goldwasser F, Bac I, Valenti M, Torres K and Pammier Y: Topoisomerase I related parameters and campothecin activity in the colon carcinoma cell lines from National Cancer Institute Anticancer screen. Cancer Res 55: 2116-2121, 1995.
9. Ate GJ, Zee VD, De Jong S, Keith WN, Hollemar H, Boonstra H and de Vries EGE: Quantitative and qualitative aspects of topoisomerase I and IIα and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumor. Cancer Res 54: 749-755, 1994.
10. Husain I, Moheer JL, Seigler HF and Bestemar JM: Elevation of topoisomerase I messenger RNA protein and catalytic activity: demonstration of tumor-type specificity and implication of cancer chemotherapy. Cancer Res 34: 539-546, 1994.
11. Evans CD, Mirski SEL, Danks MK and Cole SP: Reduced levels of topoisomerase IIα and IIβ in a multidrug-resistant lung cancer cell line. Cancer Chemother Pharmacol 34: 242-248, 1994.
12. Patel S, Austin CA and Fisher LM: Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line. Anti-cancer Drug Des 5: 149-157, 1990.
13. Hindo M, Deisseroth K, Mayes J, Aetschuler E, Jansen R, Ledley FD and Zwilly LA: Identification of a point mutation with topoisomerase II gene from a human leukemia cell line containing an Amsacrine-resistant form of topoisomerase II. Cancer Res 51: 4729-4731, 1993.
14. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y and Okada K: Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565-5569, 1987.
15. Tanizawa A and Pommier Y: Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52: 1848-1854, 1992.
16. Kubota N, Kanzawa F, Nishio K, Takeda Y, Ohmori T, Fujisawa Y, Terashima Y and Saijo N: Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem Biophys Res Commun 188: 571-577, 1992.
17. De Jong S, Zijlstra JG, de Vries EGE and Mulder NH: Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an Adriamycin resistant human small cell lung carcinoma cell line. Cancer Res 50: 304-309, 1990.
18. Feldhoft PW, Mirski SEL, Cole SPC and Sullivan DM: Altered subcellular distribution of topoisomerase IIα in drug-resistant human small cell lung cancer cell line. Cancer Res 34: 756-762, 1994.
19. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G and Kohn KW: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12: 530-542, 1994.
20. Blaney SM, Phillips LL, Packer RJ, Heideman RL, Berg SL, Adamson PC, Allen JC, Sallan SE, JAK Acki RI, Lange BJ, Reaman CH, Horowitz ME, Popolack DG and Balis FM: Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 78: 527-531, 1996.
21. Van der Zu AGJ, Hallema H, de Jong S, Boonstra H, Gauw A, Willemse PHB, Zijlstra JG and de Vries EGE: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of ovary before and after platinum/cyclophosphamide therapy. Cancer Res 51: 5915-5920, 1991.
22. Marins JC, Miller KG and Englund PJ: Decatenation of kinetoplast DNA by topoisomerases. J Biol Chem 255: 4976-4979, 1980.
23. Cardenas ME and Gasser SM: Regulation of topoisomerase II by phosphorylation: a role for casein kinase II. J Cell Sci 104: 219-224, 1993.
24. DeVore RF, Corbett AH and Osheroff N: Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinyl-amino) methane-sulfon-m-ansidide. Cancer Res 52: 2156-2161, 1992.
25. Takano H, Kohno K, Ono M, Uchida Y and Kuwano M: Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51: 3951-3957, 1991.
26. Sugimoto Y, Tsukahara S, Oh-Hara T, Liu LF and Tsuro T: Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50: 7962-7965, 1990.
27. Beck WT: Unkatting the complexities of multidrug resistance: the involvement of DNA topoisomerase in drug action and resistant. J Natl Cancer Inst 81: 1683-1685, 1989.
28. Ellis AL, Nowak B, Plunkett W and Zwelling LA: Quantification of topoisomerase DNA complex in leukemic cells from patients undergoing therapy with a topoisomerase-direct agent. Cancer Chemother Pharmacol 34: 249-256, 1994.